The recent proposal by NHS England focuses on restricting puberty blockers for children questioning their gender to controlled clinical trials, raising serious ethical concerns.
With a significant rise in referrals, especially among those registered female at birth, the medical community is challenged to reconsider how gender identity treatment is approached.
Health Secretary Wes Streeting's commitment to funding a clinical trial reflects ongoing debates and hesitance within the healthcare sector regarding the safety and appropriateness of puberty blockers.
Critics question the ethics of conducting trials on minors, particularly around potential psychological and physical harms, highlighting a critical dilemma in modern medical ethics.
Collection
[
|
...
]